Giant axonal neuropathy: Difference between revisions
CSV import |
CSV import |
||
| Line 1: | Line 1: | ||
{{SI}} | |||
{{Infobox medical condition | |||
| name = Giant axonal neuropathy | |||
| image = [[File:autorecessive.svg|200px]] | |||
| caption = Giant axonal neuropathy is inherited in an [[autosomal recessive]] pattern. | |||
| synonyms = GAN | |||
| pronounce = | |||
| specialty = [[Neurology]], [[Genetics]] | |||
| symptoms = [[Peripheral neuropathy]], [[ataxia]], [[dysarthria]], [[seizures]], [[intellectual disability]] | |||
| onset = Childhood | |||
| duration = Progressive | |||
| causes = Mutations in the [[GAN (gene)|GAN gene]] | |||
| risks = | |||
| diagnosis = [[Genetic testing]], [[nerve biopsy]] | |||
| differential = [[Charcot-Marie-Tooth disease]], [[Friedreich's ataxia]] | |||
| treatment = Supportive care, [[physical therapy]], [[occupational therapy]] | |||
| medication = | |||
| prognosis = Variable, often progressive | |||
| frequency = Rare | |||
| deaths = | |||
}} | |||
{{DISPLAYTITLE:Giant Axonal Neuropathy}} | {{DISPLAYTITLE:Giant Axonal Neuropathy}} | ||
== Introduction == | |||
== | |||
'''Giant Axonal Neuropathy''' (GAN) is a rare [[genetic disorder]] that affects the [[nervous system]]. It is characterized by the abnormal growth of [[axons]], which are the long, threadlike extensions of [[neurons]] that transmit [[nerve impulses]]. This condition is inherited in an [[autosomal recessive]] pattern, meaning that both copies of the gene in each cell have mutations. | '''Giant Axonal Neuropathy''' (GAN) is a rare [[genetic disorder]] that affects the [[nervous system]]. It is characterized by the abnormal growth of [[axons]], which are the long, threadlike extensions of [[neurons]] that transmit [[nerve impulses]]. This condition is inherited in an [[autosomal recessive]] pattern, meaning that both copies of the gene in each cell have mutations. | ||
== Pathophysiology == | == Pathophysiology == | ||
GAN is caused by mutations in the [[GAN gene]], which provides instructions for making a protein called gigaxonin. This protein is involved in the breakdown of intermediate filaments, which are part of the cell's [[cytoskeleton]]. In individuals with GAN, the abnormal gigaxonin leads to the accumulation of intermediate filaments in the axons, causing them to swell and become dysfunctional. | GAN is caused by mutations in the [[GAN gene]], which provides instructions for making a protein called gigaxonin. This protein is involved in the breakdown of intermediate filaments, which are part of the cell's [[cytoskeleton]]. In individuals with GAN, the abnormal gigaxonin leads to the accumulation of intermediate filaments in the axons, causing them to swell and become dysfunctional. | ||
== Clinical Features == | == Clinical Features == | ||
The symptoms of Giant Axonal Neuropathy typically begin in early childhood. Affected individuals often experience: | The symptoms of Giant Axonal Neuropathy typically begin in early childhood. Affected individuals often experience: | ||
| Line 14: | Line 32: | ||
* [[Optic atrophy]], which can lead to vision problems. | * [[Optic atrophy]], which can lead to vision problems. | ||
* [[Curly hair]], which is a distinctive feature in many patients. | * [[Curly hair]], which is a distinctive feature in many patients. | ||
== Diagnosis == | == Diagnosis == | ||
Diagnosis of GAN is based on clinical evaluation, family history, and genetic testing. [[Nerve biopsy]] may reveal the characteristic giant axons filled with disorganized neurofilaments. Genetic testing can confirm mutations in the GAN gene. | Diagnosis of GAN is based on clinical evaluation, family history, and genetic testing. [[Nerve biopsy]] may reveal the characteristic giant axons filled with disorganized neurofilaments. Genetic testing can confirm mutations in the GAN gene. | ||
== Management == | == Management == | ||
There is currently no cure for Giant Axonal Neuropathy. Management focuses on symptomatic treatment and supportive care, including: | There is currently no cure for Giant Axonal Neuropathy. Management focuses on symptomatic treatment and supportive care, including: | ||
| Line 24: | Line 40: | ||
* [[Speech therapy]] for communication difficulties. | * [[Speech therapy]] for communication difficulties. | ||
* [[Orthopedic devices]] to support weakened limbs. | * [[Orthopedic devices]] to support weakened limbs. | ||
== Prognosis == | == Prognosis == | ||
The progression of GAN varies among individuals, but it is generally a progressive disorder. Most affected individuals experience a decline in motor and sensory functions over time, leading to significant disability. | The progression of GAN varies among individuals, but it is generally a progressive disorder. Most affected individuals experience a decline in motor and sensory functions over time, leading to significant disability. | ||
== See also == | |||
== | |||
* [[Peripheral neuropathy]] | * [[Peripheral neuropathy]] | ||
* [[Autosomal recessive disorder]] | * [[Autosomal recessive disorder]] | ||
* [[Genetic testing]] | * [[Genetic testing]] | ||
[[Category:Genetic disorders]] | [[Category:Genetic disorders]] | ||
[[Category:Neurological disorders]] | [[Category:Neurological disorders]] | ||
Latest revision as of 20:21, 6 April 2025

Editor-In-Chief: Prab R Tumpati, MD
Obesity, Sleep & Internal medicine
Founder, WikiMD Wellnesspedia &
W8MD medical weight loss NYC and sleep center NYC
| Giant axonal neuropathy | |
|---|---|
| Synonyms | GAN |
| Pronounce | |
| Specialty | Neurology, Genetics |
| Symptoms | Peripheral neuropathy, ataxia, dysarthria, seizures, intellectual disability |
| Complications | N/A |
| Onset | Childhood |
| Duration | Progressive |
| Types | N/A |
| Causes | Mutations in the GAN gene |
| Risks | |
| Diagnosis | Genetic testing, nerve biopsy |
| Differential diagnosis | Charcot-Marie-Tooth disease, Friedreich's ataxia |
| Prevention | N/A |
| Treatment | Supportive care, physical therapy, occupational therapy |
| Medication | |
| Prognosis | Variable, often progressive |
| Frequency | Rare |
| Deaths | |
Introduction[edit]
Giant Axonal Neuropathy (GAN) is a rare genetic disorder that affects the nervous system. It is characterized by the abnormal growth of axons, which are the long, threadlike extensions of neurons that transmit nerve impulses. This condition is inherited in an autosomal recessive pattern, meaning that both copies of the gene in each cell have mutations.
Pathophysiology[edit]
GAN is caused by mutations in the GAN gene, which provides instructions for making a protein called gigaxonin. This protein is involved in the breakdown of intermediate filaments, which are part of the cell's cytoskeleton. In individuals with GAN, the abnormal gigaxonin leads to the accumulation of intermediate filaments in the axons, causing them to swell and become dysfunctional.
Clinical Features[edit]
The symptoms of Giant Axonal Neuropathy typically begin in early childhood. Affected individuals often experience:
- Peripheral neuropathy, leading to muscle weakness and loss of sensation in the arms and legs.
- Ataxia, or lack of coordination.
- Dysarthria, or difficulty speaking.
- Optic atrophy, which can lead to vision problems.
- Curly hair, which is a distinctive feature in many patients.
Diagnosis[edit]
Diagnosis of GAN is based on clinical evaluation, family history, and genetic testing. Nerve biopsy may reveal the characteristic giant axons filled with disorganized neurofilaments. Genetic testing can confirm mutations in the GAN gene.
Management[edit]
There is currently no cure for Giant Axonal Neuropathy. Management focuses on symptomatic treatment and supportive care, including:
- Physical therapy to maintain mobility and muscle strength.
- Occupational therapy to assist with daily activities.
- Speech therapy for communication difficulties.
- Orthopedic devices to support weakened limbs.
Prognosis[edit]
The progression of GAN varies among individuals, but it is generally a progressive disorder. Most affected individuals experience a decline in motor and sensory functions over time, leading to significant disability.